XENE icon

Xenon Pharmaceuticals

35.02 USD
-0.52
1.46%
At close May 9, 4:00 PM EDT
Pre-market
34.73
-0.29
0.83%
1 day
-1.46%
5 days
-8.52%
1 month
10.86%
3 months
-10.78%
6 months
-20.54%
Year to date
-12.82%
1 year
-17.58%
5 years
172.32%
10 years
157.50%
 

About: Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.

Employees: 327

0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 3 analysts

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

5,216% more call options, than puts

Call options by funds: $4.36M | Put options by funds: $82K

45% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 20

44% more funds holding in top 10

Funds holding in top 10: 9 [Q3] → 13 (+4) [Q4]

3% more funds holding

Funds holding: 201 [Q3] → 208 (+7) [Q4]

1.24% more ownership

Funds ownership: 98.82% [Q3] → 100.06% (+1.24%) [Q4]

1% more capital invested

Capital invested by funds: $2.95B [Q3] → $2.99B (+$41.4M) [Q4]

6% less repeat investments, than reductions

Existing positions increased: 65 | Existing positions reduced: 69

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$52
48%
upside
Avg. target
$53
52%
upside
High target
$55
57%
upside

3 analyst ratings

positive
100%
neutral
0%
negative
0%
Chardan Capital
Rudy Li
50% 1-year accuracy
6 / 12 met price target
57%upside
$55
Buy
Initiated
7 May 2025
Goldman Sachs
Paul Choi
67% 1-year accuracy
10 / 15 met price target
48%upside
$52
Buy
Maintained
17 Apr 2025
HC Wainwright & Co.
Douglas Tsao
22% 1-year accuracy
36 / 162 met price target
51%upside
$53
Buy
Reiterated
24 Feb 2025

Financial journalist opinion

Based on 4 articles about XENE published over the past 30 days

Neutral
GlobeNewsWire
6 days ago
Xenon to Report Q1 2025 Financial Results on May 12, 2025
VANCOUVER, British Columbia and BOSTON, May 05, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced it will report its first quarter 2025 financial results and provide a business update after the close of U.S. financial markets on Monday, May 12, 2025.
Xenon to Report Q1 2025 Financial Results on May 12, 2025
Positive
Zacks Investment Research
6 days ago
Wall Street Analysts See a 48.15% Upside in Xenon Pharmaceuticals (XENE): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 48.2% in Xenon Pharmaceuticals (XENE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts See a 48.15% Upside in Xenon Pharmaceuticals (XENE): Can the Stock Really Move This High?
Neutral
GlobeNewsWire
1 week ago
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
VANCOUVER, British Columbia and BOSTON, May 02, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced equity inducement grants to four new non-officer employees consisting of an aggregate of 78,600 share options and 1,800 performance share units (“PSUs”). All of the foregoing share options and PSUs were approved by the Compensation Committee of the Company's Board of Directors with an effective date of May 2, 2025 and were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Positive
Seeking Alpha
3 weeks ago
Xenon- A Later Stage Story
Xenon's lead asset, azetukalner, shows promise in treating focal onset seizures with positive phase IIb results and upcoming phase III data expected by end of 2025. Azetukalner's unique Kv7 potassium channel mechanism and rapid onset of action could address unmet needs in treatment-resistant epilepsy and potentially depression. Financially stable, Xenon is well-funded into 2027, with potential $1Bn market opportunity if azetukalner succeeds in focal onset seizures and expands into other indications.
Xenon- A Later Stage Story
Positive
Seeking Alpha
1 month ago
Xenon Pharmaceuticals Looks Attractive Before Epilepsy Data
Xenon Pharmaceuticals Inc.'s lead asset, azetukalner (XEN1101), shows promising phase 2b results for focal onset seizures (FOS) and is in phase 3 trials for FOS and PGTCS. Despite failing to meet the primary endpoint in an MDD trial, azetukalner's potential in epilepsy remains strong, with long-term data showing sustained seizure reduction. Financially, Xenon Pharma has a solid cash position, providing a runway of 11–13 quarters, making it an attractive investment at current low prices.
Xenon Pharmaceuticals Looks Attractive Before Epilepsy Data
Neutral
GlobeNewsWire
1 month ago
Xenon to Showcase Long-Term 36-Month Azetukalner Data at AAN 2025
VANCOUVER, British Columbia and BOSTON, April 04, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced multiple presentations at the upcoming American Academy of Neurology Annual Meeting (AAN 2025), taking place April 5-9, 2025 in San Diego, CA. Three posters will be presented, including long-term data from the ongoing X-TOLE open-label extension (OLE) study of azetukalner in patients with focal onset seizures (FOS). The Company will also present an exploratory efficacy analysis of FOS seizure subtypes from the X-TOLE study, as well as patient survey findings about the mental health and comorbidity burdens of FOS.
Xenon to Showcase Long-Term 36-Month Azetukalner Data at AAN 2025
Neutral
CNBC Television
1 month ago
Stifel's Paul Matteis says look for biotech names not dependent on the FDA amid sector uncertainty
Paul Matteis, Stifel head of biotech research, joins 'The Exchange' to discuss the biotech trade under a new FDA amid the top vaccine official resigning.
Stifel's Paul Matteis says look for biotech names not dependent on the FDA amid sector uncertainty
Neutral
GlobeNewsWire
1 month ago
Xenon to Present at Stifel 2025 Virtual CNS Forum
VANCOUVER, British Columbia and BOSTON, March 12, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced that the company will present at the Stifel 2025 Virtual CNS Forum taking place from March 18-19, 2025.
Xenon to Present at Stifel 2025 Virtual CNS Forum
Negative
Zacks Investment Research
2 months ago
Xenon Q4 Loss Narrower Than Expected, Pipeline Development in Focus
XENE reports a narrower-than-expected fourth-quarter 2024 loss. Its development programs for azetukalner in epilepsy and MDD are progressing well.
Xenon Q4 Loss Narrower Than Expected, Pipeline Development in Focus
Neutral
Seeking Alpha
2 months ago
Xenon Pharmaceuticals Inc. (XENE) Q4 2024 Earnings Call Transcript
Xenon Pharmaceuticals Inc. (NASDAQ:XENE ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Chad Fugere - Vice President, Investor Relations Ian Mortimer - President and Chief Executive Officer Chris Kenney - Chief Medical Officer Sherry Aulin - Chief Financial Officer Conference Call Participants Paul Matteis - Stifel Caroline Poacher - JPMorgan Brian Skorney - Baird Jason Gerberry - Bank of America Sarah Schram - William Blair Laura Chico - Wedbush Securities Joseph Thome - TD Cowen Douglas Tsao - H.C. Wainwright Operator Hello and thank you for standing by.
Xenon Pharmaceuticals Inc. (XENE) Q4 2024 Earnings Call Transcript
Charts implemented using Lightweight Charts™